8-K: Cypherpunk Tech Reports Q2 2026 Results, Leap Therapeutics Advances Cancer Drug

Cypherpunk Technologies announced its second quarter 2026 financial results, highlighting an increase in Zcash holdings and progress for its subsidiary Leap Therapeutics' cancer drug candidate, sirexatamab.

Summary

• Cypherpunk Technologies reported its financial results for the second quarter ended June 30, 2026.
• The company increased its Zcash (ZEC) treasury holdings to 323,394.38 ZEC, with an average purchase price of $341.83.
• Leap Therapeutics, a subsidiary, announced the publication of Phase 2 DeFianCe study results for sirexatamab (DKN-01) in Clinical Cancer Research.
• Leap Therapeutics also reached alignment with the FDA on a proposed Phase 3 trial for sirexatamab in DKK1-high metastatic colorectal cancer (mCRC).
• The company is exploring strategic options for sirexatamab, including a spin-out or partnership.
• Net income for Q2 2026 was $39.4 million, or $0.18 per diluted share, a significant improvement from a net loss of $16.6 million in Q2 2025, largely due to unrealized gains on ZEC holdings.
• Research and development expenses decreased to $0.2 million in Q2 2026 from $10.5 million in Q2 2025.
• General and administrative expenses increased to $4.5 million in Q2 2026 from $1.8 million in Q2 2025.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a mixed sentiment filing. While there are positive developments in the Leap Therapeutics pipeline and a strategic focus on Zcash, the financial results are heavily influenced by volatile digital asset holdings, and the company faces significant risks and uncertainties.

Positives

• Increased Zcash treasury holdings to 323,394.38 ZEC, representing approximately 1.92% of the total circulating supply.
• Appointment of Dev Ojha, founder of Valar Group, as an Advisor to Cypherpunk Technologies.
• Publication of Phase 2 DeFianCe study results for sirexatamab in Clinical Cancer Research, detailing efficacy, safety, and biomarker analyses.
• FDA alignment on a registrational Phase 3 trial design for sirexatamab in DKK1-high colorectal cancer, with key elements including a DKK1 biomarker-selected population and dual endpoints for accelerated and full approval.
• Sirexatamab received Fast Track designation from the FDA in May 2026 for DKK1-high mCRC.
• Significant unrealized gain of $46.0 million on ZEC treasury holdings in Q2 2026, contributing to a net income of $39.4 million.
• Substantial decrease in R&D expenses to $0.2 million in Q2 2026 from $10.5 million in Q2 2025, due to completion of clinical trials.

Negatives

• The prespecified primary endpoint (progression-free survival) in the Phase 2 DeFianCe study ITT population was not met.
• The DKK1 biomarker subgroup and interaction analyses were exploratory, based on a limited number of patients, and not adjusted for multiplicity.
• General and administrative expenses increased by $2.7 million in Q2 2026 compared to Q2 2025, primarily due to stock-based compensation and payroll increases.
• Cash and cash equivalents decreased to $7.6 million on June 30, 2026, from $14.0 million on December 31, 2025.
• Digital asset receivable (ZEC holdings) decreased to $129.4 million on June 30, 2026, from $147.4 million on December 31, 2025.
• The company is undertaking a strategic process for sirexatamab with no assurance of a favorable transaction or financing.

Risks

• High volatility of ZEC price, which can significantly impact financial statements through unrealized gains/losses.
• Potential correlation between the price of Cypherpunk's common stock and the price of ZEC.
• Risks related to the custody of ZEC and reliance on third-party services for trading and custody.
• Uncertainty regarding the success of the proposed Phase 3 trial for sirexatamab and FDA approval.
• The exploratory nature of the DKK1 biomarker analyses and the risk they may not be replicated in a prospective trial.
• The strategic process for sirexatamab may not result in any transaction or financing, or may be terminated.
• Potential for accelerated approval withdrawal if confirmatory trial requirements are not met.
• The company's ability to obtain additional capital to advance sirexatamab.

Future Outlook

The company is pursuing a strategic process for its subsidiary Leap Therapeutics' sirexatamab program, considering options like a spin-out or partnership. Leap Therapeutics has aligned with the FDA on a Phase 3 trial design for sirexatamab in DKK1-high mCRC, aiming for accelerated and full approval. Cypherpunk Technologies continues to focus on its Zcash treasury strategy and supporting core infrastructure developers.

Management Comments

• "In the second quarter, Cypherpunk built upon the momentum established earlier this year through the disciplined execution of our Zcash digital asset treasury strategy, increasing our treasury holdings to 323,394.38 ZEC, and welcoming Dev Ojha, founder of Valar Group, as an Advisor."
• "Our Leap Therapeutics subsidiary reached alignment with the FDA on a proposed Phase 3 trial in a DKK1-high, second-line, metastatic colorectal cancer population, with objective response rate as the primary endpoint to support accelerated approval and overall survival to support full approval in the United States and registration globally."
• "In an increasingly AI-driven economy, the demand for true privacy is moving from a technical preference to a civilizational necessity. Our execution in the second quarter reinforces Cypherpunks conviction in Zcash as a foundational monetary asset. By growing our ZEC treasury, expanding our world-class advisory team, and continuing to back core infrastructure developers like ZODL, we are systematically positioning Cypherpunk to capture the long-term value of digital privacy adoption."
• "In second-line colorectal cancer, we urgently need novel biomarkers that inform patients treatment options. The final data from the DeFianCe study show that baseline plasma DKK1 identifies patients with more aggressive disease, and it identifies the patients who benefit most from adding sirexatamab."
• "We need new liquid biopsy biomarkers that tell us effectively which patients will benefit from which therapy. These data support the utility of baseline plasma DKK1 as a liquid biomarker for improving response rates and survival with sirexatamab, making a compelling case for a biomarker-selected Phase 3 registrational trial."

Industry Context

StockSavvy.ai notes that Cypherpunk Technologies operates in two distinct sectors: digital assets (specifically Zcash) and biotechnology. The company's financial performance is heavily influenced by the volatile cryptocurrency market, while its long-term value proposition is tied to the success of its subsidiary's drug development pipeline. The progress in sirexatamab's Phase 3 trial design aligns with industry trends towards personalized medicine and biomarker-driven therapies in oncology.

Comparison to Industry Standards

• The Phase 2 DeFianCe study for sirexatamab did not meet its primary endpoint of progression-free survival in the intent-to-treat population, which is a common challenge in oncology drug development.
• However, the identification of a DKK1-high patient subgroup that shows significant benefit from sirexatamab is a positive development, aligning with industry efforts to refine patient selection for targeted therapies.
• The FDA's alignment on a Phase 3 trial design with dual endpoints (ORR for accelerated approval, OS for full approval) is a standard pathway for oncology drugs, particularly those with Fast Track designation.
• The company's Zcash treasury strategy is unique and not directly comparable to traditional financial institutions or technology companies, making its financial metrics highly specific to its business model.

Stakeholder Impact

• Shareholders: The significant unrealized gain on ZEC holdings positively impacts the current net income, but the volatility of ZEC poses a risk. The strategic process for sirexatamab could lead to value creation or dilution depending on the outcome.
• Patients: The progress in sirexatamab development, including FDA alignment for a Phase 3 trial and Fast Track designation, offers potential for new treatment options for DKK1-high mCRC patients.
• Creditors: The company's cash position and the ongoing strategic process for its biotech subsidiary will influence its ability to meet financial obligations.

Next Steps

• Initiate and conduct a randomized, controlled Phase 3 trial evaluating sirexatamab in combination with chemotherapy and bevacizumab in DKK1-high mCRC patients.
• Develop a blood-based companion diagnostic to identify DKK1-high patients.
• Continue the strategic process to determine the best path forward for sirexatamab, potentially involving a spin-out or partnership.
• Comply with confirmatory trial requirements if accelerated approval is pursued for sirexatamab.
• Continue to manage and potentially grow Zcash treasury holdings.

Key Dates

Recommendation

The filing presents a mixed picture. The significant unrealized gains on ZEC holdings are a temporary boost and highlight the inherent volatility of the company's digital asset strategy. While the Leap Therapeutics pipeline shows promise with FDA alignment for a Phase 3 trial and Fast Track designation, the primary endpoint of the Phase 2 study was not met, and the company is exploring strategic alternatives with no guaranteed outcome. The increased G&A expenses and reduced cash reserves warrant caution. Therefore, a 'hold' recommendation is appropriate pending further clarity on the sirexatamab strategic process and more stable financial performance independent of crypto asset fluctuations.

Keywords

Zcash, CYPH, Leap Therapeutics, sirexatamab, DKN-01, metastatic colorectal cancer, DKK1 biomarker, Phase 3 trial